What is HydroCision?
HydroCision, Inc. operates as a privately held entity at the intersection of advanced engineering and clinical application. Its core competency lies in the development and commercialization of FluidJet technology, a platform designed to address the limitations of traditional surgical tools. By utilizing fluid dynamics to perform tissue resection, the company provides a safer, more efficient alternative for surgeons in high-stakes environments such as spine surgery and interventional pain management. The company's market position is fortified by a robust intellectual property portfolio, which acts as a significant barrier to entry for competitors while enabling sustained growth in specialized medical segments.
How much funding has HydroCision raised?
HydroCision has raised a total of $36.5M across 10 funding rounds:
Series F
$5.2M
Series G
$12.7M
Debt
$3M
Debt
$623K
Private Equity
$3M
Other Financing Round
$4M
Debt
$150K
Debt
$279K
Series F (2002): $5.2M, investors not publicly disclosed
Series G (2006): $12.7M, investors not publicly disclosed
Debt (2008): $3M, investors not publicly disclosed
Debt (2010): $623K, investors not publicly disclosed
Private Equity (2017): $3M led by BioVentures Investors, LLC and Volcano Capital, LLC
Other Financing Round (2017): $4M supported by Tradewind International
Debt (2020): $150K featuring PPP
Debt (2021): $279K backed by PPP
Key Investors in HydroCision
BioVentures Investors, LLC
BioVentures MedTech Funds is dedicated to investing in innovative companies that are developing advanced medical technologies aimed at improving healthcare outcomes globally.
Volcano Capital, LLC
Volcano Capital provides funding and operational expertise to help entrepreneurs grow their healthcare businesses, focusing on early to mid-stage medical device companies.
Oxford Bioscience Partners
Oxford Bioscience Partners is an international venture capital firm specializing in life science technology based investments, with offices in Boston and Seoul.
What's next for HydroCision?
Looking ahead, HydroCision is positioned to leverage its recent capital injection to scale commercial operations and potentially expand its clinical footprint. Given the company's history of securing both equity and debt financing, the current strategic focus likely involves optimizing its supply chain and accelerating the adoption of its FluidJet platform in global markets. As the firm transitions into its next phase of maturity, the emphasis will remain on maintaining its technological edge while navigating the complex regulatory landscapes inherent to the medical device industry. Investors will be monitoring the company's ability to convert its technical superiority into consistent, long-term revenue streams across its core therapeutic areas.
See full HydroCision company page
